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Abstract 
Early hemodialysis allocation deliberations should inform our current 
considerations of what constitutes reasonable uses of extracorporeal 
membrane oxygenation. Deliberative democracy can be used as a 
strategy to gather a plurality of views, consider criteria, and guide policy 
making. 
 
Introduction 
Decision making about how to use new life-saving technologies, especially in life-or-
death situations, is often fraught. Debate has long persisted about the appropriateness 
of hemodialysis (HD) for patients who are elderly and frail.1 Decisions about use of 
extracorporeal membrane oxygenation (ECMO)—a machine-facilitated process that 
oxygenates and circulates blood for patients with impaired heart or lung function—are 
similarly clinically and ethically complex. In this article, we first examine the growth of 
ECMO and consider cautionary lessons of early HD allocation deliberations for current 
decision making about ECMO use. We then highlight a recent multisociety statement 
that calls for stakeholder input in defining the boundaries of ECMO use at the end of life. 
Finally, we suggest that a deliberative democratic process can provide a better way 
forward in decision making about deployment of new technologies in a health care 
environment in which costs continue to escalate. 
 
ECMO in Its Adolescence 
ECMO has been in clinical use for more than 40 years. In 1944, blood was first 
oxygenated while passing through cellophane artificial kidney membranes, and the idea 
of ECMO was born.2 In 1972, ECMO was first successfully used to treat an adult with 
posttraumatic respiratory failure.3 In its first decade of use, however, patients’ survival 
rate was around 10%.3 The next 40 years were a slow period of growth in use of ECMO.4 
Complications from bleeding, clotting, infections, and resource limitations impaired its 
regular use in adults until the mid-2000s.5 Between 2002 and 2006, for example, fewer 
than 1000 adults annually received ECMO therapy.6 Since 2009, there has been a 
considerable increase in adult ECMO use, with 18 684 patients receiving ECMO therapy 
between 2008 and 2014.7 
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Currently, ECMO is used as a bridge to surgical intervention (a temporary modality) or as 
a bridge to recovery from respiratory and cardiac conditions (even if that time is 
measured in years8) when traditional modalities have failed. Already in development is a 
small implantable ECMO for bridge to recovery or destination therapy,9 so one can easily 
envision a time in the coming decades in which ECMO will be used increasingly as 
destination therapy.  
 
Ethical Foundations of Clinical Criteria Used in HD Decision Making 
Growth in ECMO use was similar to that of HD between 1940 and 1960. Originally 
envisioned as a short-term organ support device that would bridge a patient to receiving 
an organ, HD is now commonly used to manage patients’ care for years. In the 1930s 
and 1940s, HD for acute renal failure was to be complimented with dietary treatment.10 
It is unlikely that early “protonephrologists” envisioned treating end-stage renal disease 
(ESRD) with HD, as is currently done, but once repeated vascular access was developed 
in 1960,11 HD became a feasible maintenance therapy. This breakthrough led to the 
establishment of the first outpatient dialysis center, the Seattle Artificial Kidney Center 
(now the Northwest Kidney Centers), in 1962.12 HD use in treating chronic disease 
ballooned when Medicare funding for dialysis began in 1972.11 As of 2015, 468 000 
patients were maintained on chronic HD.13 
 
At the Seattle Artificial Kidney Center, ethics committees helped determine how to 
allocate limited HD resources. First, a team of physicians (the Medical Advisory 
Committee) created screening criteria for assessing patients’ eligibility for HD in terms of 
their comorbid conditions and risk factors. Patients who passed this phase of evaluation 
according to clinical criteria were then evaluated by the Admissions and Policy 
Committee (a group of Seattle area citizens comprising a lawyer, a clergyman, a 
housewife, a banker, a state official, and a surgeon), which sought to allocate HD access 
in terms of patients’ social worth. This controversial second phase of decision making 
was one of the first times an organization formally drew upon community input to 
allocate a scarce resource.14 
 
An article in Life magazine about this decision-making process sparked national debate 
about whether and how one’s social worth should be used to allocate access to medical 
technologies.15 At the time of this debate, the clinical criteria were generally seen as 
necessary and relatively uncontroversial. Since then, however, even the presumed 
objectivity of clinical criteria has been questioned. For example, challenges to 
neurological criteria for death have been raised.16 In this context, deciding the medical 
appropriateness of treatment outside of true medical futility can be very controversial. 
 
In 2015, the second author (GTB) collaborated on a multiple critical care societies 
statement to address “potentially inappropriate treatment” in intensive care units.17 This 
document considered how clinicians and institutions should respond to patient or 
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surrogate requests for treatments that clinicians regard as medically inappropriate, an 
issue that has been a persistent source of clinical ethical complexity. In the 1960s, using 
HD to treat ESRD in patients with other life-limiting diseases would have been 
considered a potentially inappropriate treatment. Even today, there is support for the 
view that dialysis for certain populations is inappropriate.18 Given the controversy around 
defining and responding to requests for inappropriate treatment, how should indications 
for ECMO be assessed and how should ECMO be used? 
 
Democratic Deliberation About Health Technology Uses 
The 2015 multisociety statement called for the medical profession to “engage in efforts 
to influence opinion and develop policies and legislation about when life-prolonging 
technologies should not be used.”17 This document further specified that such 
engagement requires diverse stakeholder input in order to be ethically acceptable in a 
pluralistic society. What would it look like to gather pluralistic stakeholder input about 
ECMO use? 
 
Deliberative democracy (DD) is one model for gathering stakeholder input about value-
laden and often controversial topics. Amy Gutmann and Dennis Thompson have defined 
DD as “a form of government in which free and equal citizens (and their representatives) 
… justify decisions in a process in which they give one another reasons that are mutually 
acceptable and generally accessible, with the aim of reaching conclusions that are 
binding in the present on all citizens but open to challenge in the future.”19 DD involves 
asking a small representative sample of stakeholders (selected by an organizing body for 
a given value-laden topic and a DD facilitator) to come together to agree upon a 
response to a controversial question or policy. DD requires a structured process that 
allows for open information sharing among all parties and requires a skilled facilitator in 
the DD process.19 
 
Governments and large institutions have used DD to inform health policy. In Great 
Britain, the National Institute for Health and Care Excellence (NICE) has employed a 
Citizens Council.20 This body of 30 members of the public represents the demographic 
makeup of Great Britain and is assembled to give input on topics that NICE has chosen.21 
(See Table for topics recently deliberated upon by the NICE Citizens Council.)  
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Table. Sampling of Topics Deliberated Upon by the National Institute for Health and Care 
Excellence Citizen Council 
 
How should NICE assess future costs and health benefits?a 
In what circumstances should NICE recommend interventions where the cost per 
QALY is above the threshold range of £20 000 to £30 000?b 
Is there a preference to save the life of people in imminent danger of dying?c 
Are there circumstances in which the age of a person should be taken into account 
when NICE is making a decision about how treatments should be used in the National 
Health Service?d 
Abbreviations: NICE, National Institute for Health and Care Excellence; QALY, quality-adjusted life year. 
a From National Institute for Health and Care Excellence Citizens Council.22 
b From National Institute for Health and Care Excellence Citizens Council.23 
c From National Institute for Health and Care Excellence Citizens Council.24 
d From National Institute for Health and Care Excellence Citizens Council.25 
 
In the early 2000s, the Romanow Commission on the Future of Health Care in Canada 
also convened a series of DD-based conversations with almost 500 representative 
Canadian citizens on health reform in Canada.26 These sessions helped inform a final 
government report that recommended sweeping changes to encourage the 
sustainability of Canada’s health care system.27 
 
Although the strong centrally managed health care systems of Canada and Great Britain 
differ in important ways from the individualistic and decentralized health structures in 
the United States, these 2 examples of DD informing health policy align with the 
multisociety statement goal of “engag[ing] in efforts to influence opinion and develop 
policies and legislation about when life-prolonging technologies should not be used.”17 
So how could a DD-based approach to ECMO use proceed in the United States? 
 
Operationalizing DD for ECMO 
There is precedent in the United States for policy making concerning difficult value-laden 
health care decisions. The Organ Procurement and Transplantation Network (OPTN) 
coordinates organ allocation through the United Network for Organ Sharing (UNOS). 
OPTN allows public comment on proposed policy changes but does not use a true DD 
process in discussions regarding policy changes. Allocation of transplant organs is 
analogous to deployment of scarce technological resources like ECMO—both involve 
highly value-laden decisions with many stakeholders and life-or-death consequences. 
 
The Extracorporeal Life Support Organization (ELSO) is “an international non-profit 
consortium of health care institutions who are dedicated to the development and 
evaluation of novel therapies for support of failing organ systems.”28 Its origins parallel 
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the early development of UNOS in that it consists of a registry “to support clinical 
research, support regulatory agencies, and support individual ELSO centers.”28 ELSO 
could coordinate DD processes to inform policies regarding ECMO deployment by 
convening stakeholder participants (likely to include citizens, physicians, and payers) and 
a DD facilitator. Potential questions for DD facilitators to ask participants in a DD process 
could include the following: 
 
1. Which, if any, comorbid conditions are absolute contraindications to ECMO use? 
2. Should a quality-adjusted life year (QALY) analysis inform ECMO use? 
3. Should ECMO use be limited to regional ECMO centers? 
 
Establishing prospective criteria based on responses to these questions by participants 
in a DD process could help generate robust and thoughtful engagement regarding the 
clinically beneficial limits of ECMO; help avoid current idiosyncratic bedside clinical 
decision making about when to recommend ECMO; and be used as the basis for refining 
national professional guidelines for ECMO use. Such a process and the resultant 
guidelines could also be used to inform broader debates about the social and cultural 
relevance of technology use at the end of life.  
 
ECMO Guidelines 
The rise of ECMO as extracorporeal organ support—with future potential for organ 
replacement therapy—shares many similarities with the rise of HD. Just as in the early 
days of HD, criteria for appropriate use of ECMO remain vague and undefined. Lessons 
from early decision making about HD use and subsequent shifts in social attitudes about 
intensive care suggest that set boundaries for new technology use in health care should 
be prospective and transparent, include multiple stakeholders or their representatives, 
and be open to challenge and revision as the technology matures and as clinical, social, 
and cultural norms evolve. As we have suggested here, DD-based approaches to policy 
making offer one strategy for including stakeholders’ voices in refining guidance for 
bedside clinicians about how and when to use ECMO. This technology is currently in its 
adolescence—rapidly growing, developing, and testing the boundaries of its potential—
and ECMO policy making should be informed by many and applied broadly to help 
clinicians help patients. 
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